Mount Sinai Local Business

Local business in Mount Sinai, NY

  • Monday Nov 10 | via Reuters 

    RPT - INSIGHT-After hep C cure, companies target nex...

    Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation .

    Comment?

    Related Topix: Biotech, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Alcoholism, Mount Sinai, NY

  • Sunday Nov 9 | via Medical Daily 

    After Hepatitis C Cure, Companies Target Next Big Li...

    Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation .

    Comment?

    Related Topix: Biotech, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Alcoholism, Mount Sinai, NY

  • Sunday Nov 9 | via Reuters 

    INSIGHT-After hep C cure, companies target next big ...

    Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation .

    Comment?

    Related Topix: Biotech, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Alcoholism, Mount Sinai, NY